AI-Powered Precision Decision-Making for Pancreatic Diseases

NCT07439757 · tracked via the Priya Life Science China tracker

Sponsor

Changhai Hospital

Phase

Observational

Started

2026-03-01

Last updated

2026-02-27

Condition(s) studied

Pancreatic CancerDiagnose DiseaseIPMN, PancreaticPancreatic Cystic LesionsChronic PancreatitisPancreatic Neuroendocrine TumorAcute Pancreatitis (AP)

Investigational drug(s) / intervention(s)

Diagnosis by Artificial Intelligence model

Diagnosis by Artificial Intelligence model: To develop an artificial intelligence-based classification management system for pancreatic diseases, achieving automated and precise classification. Contrast-enhanced CT images from all study subjects will be analyzed by the AI system to generate classification results, categorizing patients into three groups: INTERVENTIOM, INTENSIVE SURVEILLANCE or ROUTINE SURVEILLANCE.

Study summary

This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery/treatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Clinically suspected pancreatic disease. * Scheduled to undergo contrast-enhanced CT. * Signed informed consent form indicating agreement to participate. Exclusion Criteria: * History of pancreatic surgery. * Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal/hepatic dysfunction. * Suboptimal image quality affecting diagnosis. * Concurrent participation in another interventional clinical trial. * Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.

Primary outcome measure(s)

Classification accuracy — From date of contrast-enhanced CT scan to 1 year
The percentage of cases correctly classified by AI out of the total number of cases.

Trial sites (1)

Facility	City	Region	Status
Changhai Hospital	Shanghai	China	Recruiting

More Changhai Hospital trials in China

Evaluation of a CAM System for Colorectal Polyp Size Measurement Recruiting

Investigation Into the Integration of Intracavitary Cryoablation and Immunotherapy in Bladder-Preserving Therapy Recruiting

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases Recruiting

Single Plastic Stent Vs. Fully Covered Self-Expanding Metal Stent on Benign Biliary Stricture Secondary to Chronic Pancreatitis Recruiting

Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD Starting soon

Other trials for the same condition

An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer Recruiting

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) Recruiting

Single Plastic Stent Vs. Fully Covered Self-Expanding Metal Stent on Benign Biliary Stricture Secondary to Chronic Pancreatitis Recruiting

Baduanjin for Quality of Life in Pancreatic Cancer Chemotherapy Starting soon

Bowel Sound in Predicting the Severity of Acute Pancreatitis: Protocol of a Prospective, Multi-center Study Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07439757 on ClinicalTrials.gov ↗ ← All trials in China